1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Kinase Inhibitors: Global Markets

Kinase Inhibitors: Global Markets

  • June 2012
  • -
  • BCC Research
  • -
  • 219 pages

INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.

This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.

A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.

R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in kinase inhibitor manufacture and use. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies active in the kinase inhibitor industry were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are: Reagents for Chromatography; Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems - Technologies and Global Markets; Orthopedic Drugs, Implants and Devices - Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging - Global Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs - Technologies and Global Markets; Contraceptives - Technologies and Global Markets; Liver Disease Treatments - The Global Market; Hormone Replacement Therapies and Other Hormone Therapies - Global Markets; Cardiovascular Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies and Global Markets.

Table Of Contents

Kinase Inhibitors: Global Markets
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 1
STUDY OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
INTENDED AUDIENCE 1
SCOPE OF THE STUDY 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 2
RELATED BCC RESEARCH REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 SUMMARY 5
SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 6
SUMMARY FIGURE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
CHAPTER 3 OVERVIEW 8
DEFINITIONS 8
ENZYME INHIBITORS 8
WHY ENZYME INHIBITION? 8
USE OF ENZYME INHIBITORS 9
Mechanism of Enzyme Inhibition 9
Types of Enzyme Inhibitors 9
CLASSIFICATION OF ENZYME INHIBITORS 10
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10
KINASE INHIBITORS 11
HISTORY OF PROTEIN KINASES 12
TABLE 2 HISTORY OF PROTEIN KINASES 12
TYPES OF KINASE INHIBITORS 13
TABLE 3 TYPES OF KINASE INHIBITORS 13
Small Molecule Inhibitors 13
TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14
Antibody (Monoclonal) Inhibitors 14
CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION 14
SERINE/THREONINE KINASE INHIBITORS 14
TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15
TYROSINE KINASE INHIBITORS 15
Receptor Tyrosine Kinase (RTK) Inhibitors 16
TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16
Non-Receptor Tyrosine Kinase (NRTK) Inhibitors 16
TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16
CLASSIFICATION BY SITE OF ACTION 17
TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17
CHAPTER 4 REGULATORY ASPECTS 20
TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20
TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21
TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY
2012 22
TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23
MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS 24
TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE
INHIBITORS 24
TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE
KINASE INHIBITORS 24
TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE
KINASE INHIBITORS 24
TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE
KINASE INHIBITORS 25
TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25
CHAPTER 5 NEW DEVELOPMENTS 27
(RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 27
TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27
TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)
TKIS 28
TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)
TKIS 28
TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
(VEGFR) TKIS 28
(NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 29
TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29
TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29
TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29
MULTIKINASE INHIBITORS 30
TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30
SERINE/THREONINE KINASE INHIBITOR 31
TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31
TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31
TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31
OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT 31
CHAPTER 6 GLOBAL MARKETS 34
MARKET ANALYSIS 34
TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35
FIGURE 1 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 35
TYROSINE KINASE INHIBITORS 36
TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($
MILLIONS) 36
FIGURE 2 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016 ($ MILLIONS) 36
Receptor Tyrosine Kinase Inhibitors 37
EGFR 38
PDGFR 38
VEGFR 38
HER2 39
Market Overview 39
Market Revenue 40
TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016
($ MILLIONS) 40
FIGURE 3 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 40
Non-Receptor Tyrosine Kinase Inhibitors 41
BCR-ABL 41
Janus Kinase (JAK) Inhibitor 42
Mesenchymal Epithelial Transition Growth Factor (c-MET) 42
Spleen Tyrosine Kinase (SYK) Inhibitors 42
Market Overview 43
Market Revenue 43
TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH
2016 ($ MILLIONS) 43
FIGURE 4 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
($ MILLIONS) 43
Multikinase Inhibitors 44
Market Overview 44
Market Revenue 45
TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($
MILLIONS) 45
FIGURE 5 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($
MILLIONS) 45
SERINE/THREONINE KINASE INHIBITORS 46
mTOR Kinase Inhibitors 46
B RAF 46
RHO Kinase Inhibitors 47
Cyclin Dependant Kinase Inhibitor 47
Aurora Kinase Inhibitors 47
MAP/MEK Kinase Inhibitors 47
JNK Inhibitors 48
Protein Kinase C Inhibitors 48
PI3K Inhibitors 48
Market Overview 49
Market Revenue 49
TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($
MILLIONS) 49
FIGURE 6 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 50
MONOCLONAL ANTIBODY KINASE INHIBITOR 50
Humanized Monoclonal Antibody 51
Chimeric Monoclonal Antibody 51
Human Monoclonal Antibody 52
Market Overview 52
Market Revenue 53
TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 53
FIGURE 7 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016
($ MILLIONS) 53
MARKET SHARE 54
RECEPTOR TYROSINE KINASE INHIBITORS 54
TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
NON-RECEPTOR TYROSINE KINASE INHIBITORS 55
MULTI-TARGET KINASE INHIBITORS 55
TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
FIGURE 9 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
SERINE/THREONINE KINASE INHIBITORS 56
TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 56
FIGURE 10 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 56
MONOCLONAL ANTIBODY KINASE INHIBITORS 57
TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 57
FIGURE 11 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION,
2010 (%) 57
MARKET BY APPLICATIONS 58
MARKET REVENUE 59
TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($
MILLIONS) 60
FIGURE 12 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($
MILLIONS) 60
ANTINEOPLASTIC AGENTS 60
TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 64
FIGURE 13 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 64
IMMUNOSUPPRESSANTS 64
TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
THROUGH 2016 ($ MILLIONS) 65
FIGURE 14 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 65
AGE-RELATED MACULAR DEGENERATION 66
TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 67
FIGURE 15 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 67
MARKET SHARE 68
TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 68
FIGURE 16 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 68
CHAPTER 7 MARKETS IN THE UNITED STATES 70
MARKET ANALYSIS 70
TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 70
FIGURE 17 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 70
TYROSINE KINASE INHIBITORS 71
TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71
FIGURE 18 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 72
Receptor Tyrosine Kinase Inhibitors 72
EGFR 73
PDGFR 73
VEGFR 73
HER2 74
Market Overview 74
Market Revenue 75
TABLE 47 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 75
FIGURE 19 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 75
Non-Receptor Tyrosine Kinase Inhibitors 76
BCR-ABL 76
Janus Kinase (JAK) Inhibitor 77
Mesenchymal Epithelial Transition Growth Factor (c-MET) 77
Spleen Tyrosine Kinase (SYK) Inhibitors 77
Market Overview 78
Market Revenue 78
TABLE 48 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 78
FIGURE 20 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 78
Multikinase Inhibitors 79
Market Overview 79
Market Revenue 80
TABLE 49 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016 ($
MILLIONS) 81
FIGURE 21 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($ MILLIONS) 81
SERINE/THREONINE KINASE INHIBITORS 81
M TOR Kinase Inhibitors 81
B RAF 82
RHO Kinase Inhibitors 82
Cyclin Dependant Kinase Inhibitor 82
Aurora Kinase Inhibitors 82
MAP/MEK Kinase Inhibitors 83
JNK Inhibitors 83
Protein Kinase C Inhibitors 83
PI3K Inhibitors 84
Market Overview 84
Market Revenue 85
TABLE 50 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 85
FIGURE 22 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 86
MONOCLONAL ANTIBODY KINASE INHIBITOR 86
Humanized Monoclonal Antibody 87
Chimeric Monoclonal Antibody 87
Human Monoclonal Antibody 88
Market Overview 88
Market Revenue 89
TABLE 51 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016
($ MILLIONS) 89
FIGURE 23 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016 ($
MILLIONS) 89
MARKET SHARE OF INDUSTRY LEADERS IN U.S 90
RECEPTOR TYROSINE KINASE INHIBITORS 90
TABLE 52 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 90
FIGURE 24 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 90
NON-RECEPTOR TYROSINE KINASE INHIBITORS 90
MULTI-TARGET KINASE INHIBITORS 91
TABLE 53 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 91
FIGURE 25 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 91
SERINE/ THREONINE KINASE INHIBITORS 91
TABLE 54 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 91
FIGURE 26 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 92
ANTIBODY KINASE INHIBITORS 92
TABLE 55 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
(%) 93
FIGURE 27 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
(%) 93
MARKET APPLICATIONS 93
MARKET REVENUE 94
TABLE 56 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016 ($
MILLIONS) 94
FIGURE 28 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($
MILLIONS) 95
ANTINEOPLASTIC AGENTS 95
TABLE 57 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 99
FIGURE 29 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 99
IMMUNOSUPPRESSANTS 100
TABLE 58 U.S. MARKET FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 100
FIGURE 30 U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 100
AGE-RELATED MACULAR DEGENERATION 101
TABLE 59 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 102
FIGURE 31 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 102
MARKET SHARE 103
TABLE 60 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103
FIGURE 32 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103
CHAPTER 8 MARKETS IN EUROPE 105
MARKET ANALYSIS 105
TABLE 61 EUROPEAN MARKET FOR KINASE INHIBITORS THROUGH 2016 ($ MILLIONS) 105
FIGURE 33 EUROPEAN MARKET FOR KINASE INHIBITORS, 2009- 2016 ($ MILLIONS) 105
TYROSINE KINASE INHIBITORS 106
TABLE 62 EUROPEAN MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 106
FIGURE 34 EUROPEAN MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 106
Receptor Tyrosine Kinase Inhibitors 107
EGFR 107
PDGFR 107
VEGFR 108
HER2 108
Market Overview 109
Market Revenue 109
TABLE 63 EUROPEAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 109
FIGURE 35 EUROPEAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
($ MILLIONS) 110
Non-Receptor Tyrosine Kinase Inhibitors 110
BCR-ABL 111
Janus Kinase (JAK) Inhibitor 111
Mesenchymal Epithelial Transition Growth Factor (c-MET) 111
Spleen Tyrosine Kinase (SYK) Inhibitors 112
Market Overview 112
Market Revenue 113
TABLE 64 EUROPEAN MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR,
THROUGH 2016 ($ MILLIONS) 113
Multikinase Inhibitors 113
Market Overview 113
Market Revenue 114
TABLE 65 EUROPEAN MARKET FOR MULTIKINASE TYROSINE KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 114
FIGURE 36 EUROPEAN MARKET FOR MULTIKINASE TYROSINE KINASE INHIBITORS,
2009-2016 ($ MILLIONS) 115
SERINE/THREONINE KINASE INHIBITORS 115
M TOR Kinase Inhibitors 115
B-RAF Kinase Inhibitors 115
RHO Kinase Inhibitors 116
Cyclin-Dependant Kinase Inhibitor 116
Aurora Kinase Inhibitors 116
MAP/MEK Kinase Inhibitors 117
JNK Inhibitors 117
Protein Kinase C Inhibitors 117
PI3K Inhibitors 118
Market Overview 118
Market Revenue 119
TABLE 66 EUROPEAN MARKET FOR SERINE/THREONINE KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 119
FIGURE 37 EUROPE MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 119
MONOCLONAL ANTIBODIES 120
Humanized Monoclonal Antibody 121
Chimeric Monoclonal Antibody 121
Human Monoclonal Antibody 121
Market Overview 121
Market Revenue 123
TABLE 67 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 123
FIGURE 38 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,
2009-2016 ($ MILLIONS) 123
MARKET SHARES OF INDUSTRY LEADERS IN EUROPE 124
RECEPTOR TYROSINE KINASE INHIBITORS 124
TABLE 68 EUROPEAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 125
FIGURE 39 EUROPEAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 125
NON-RECEPTOR TYROSINE KINASE INHIBITORS 125
MULTI-TARGET KINASE INHIBITORS 125
TABLE 69 EUROPEAN MARKET SHARE OF MULTI-TARGET KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 126
FIGURE 40 EUROPEAN MARKET SHARE OF MULTI-TARGET KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 126
SERINE/ THREONINE KINASE INHIBITORS 126
TABLE 70 EUROPEAN MARKET SHARE OF SERINE/THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 127
FIGURE 41 EUROPEAN MARKET SHARE OF SERINE/THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 127
ANTIBODY KINASE INHIBITORS 127
TABLE 71 EUROPEAN MARKET SHARES OF ANTIBODY KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 127
FIGURE 42 EUROPEAN MARKET SHARE OF ANTIBODY KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 127
MARKET APPLICATIONS 128
MARKET REVENUE 129
TABLE 72 EUROPEAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016
($ MILLIONS) 130
FIGURE 43 EUROPEAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($
MILLIONS) 130
ANTINEOPLASTIC AGENTS 130
TABLE 73 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, THROUGH 2016 ($ MILLIONS) 134
FIGURE 44 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, 2009-2016 ($ MILLIONS) 134
IMMUNOSUPPRESSANTS 135
TABLE 74 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
THROUGH 2016 ($ MILLIONS) 136
FIGURE 45 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS, 2009-2016 ($ MILLIONS) 136
AGE-RELATED MACULAR DEGENERATION 136
TABLE 75 EUROPEAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 137
FIGURE 46 EUROPEAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED
MACULAR DEGENERATION, 2009-2016 ($ MILLIONS) 137
Market Share 138
TABLE 76 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, IN EUROPE, 2010 (%) 138
FIGURE 47 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, IN EUROPE, 2010
(%) 138
CHAPTER 9 MARKETS IN ASIA 140
MARKET ANALYSIS 140
TABLE 77 ASIAN MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 141
FIGURE 48 ASIAN MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 141
TYROSINE KINASE INHIBITORS 142
TABLE 78 ASIAN MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 142
FIGURE 49 ASIAN MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 142
Receptor Tyrosine Kinase Inhibitors 143
EGFR 143
PDGFR 143
VEGFR 144
HER2 144
Market Overview 144
Market Revenue 145
TABLE 79 ASIAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 145
FIGURE 50 ASIAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS 2009-2016 ($
MILLIONS) 145
Non-Receptor Tyrosine Kinase Inhibitors 146
BCR-ABL 146
Janus Kinase (JAK) Inhibitor 147
Mesenchymal Epithelial Transition Growth Factor (c-MET) 147
Spleen Tyrosine Kinase (SYK) Inhibitors 147
Market Overview 148
Market Revenue 148
TABLE 80 ASIAN MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 148
Multikinase Inhibitors 148
Market Overview 148
Market Revenue 149
TABLE 81 ASIAN MARKET FOR MULTIKINASE TYROSINE KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 149
FIGURE 51 ASIAN MARKET FOR MULTIKINASE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 149
SERINE/THREONINE KINASE INHIBITORS 150
M TOR Kinase Inhibitors 150
B RAF Kinase Inhibitors 151
RHO Kinase Inhibitors 151
Cyclin-Dependant Kinase Inhibitor 151
Aurora Kinase Inhibitors 151
MAP/MEK Kinase Inhibitors 152
JNK Inhibitors 152
Protein Kinase C Inhibitors 152
PI3K Inhibitors 153
Market Overview 153
Market Revenue 153
TABLE 82 ASIAN MARKET FOR SERINE/THREONINE KINASE INHIBITORS THROUGH 2016 ($
MILLIONS) 153
FIGURE 52 ASIAN MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 154
MONOCLONAL ANTIBODIES 154
Humanized Monoclonal Antibody 155
Chimeric Monoclonal Antibody 155
Human Monoclonal Antibody 155
Market Overview 156
Market Revenue 157
TABLE 83 ASIAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 157
FIGURE 53 ASIAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS, 2009-2016
($ MILLIONS) 157
MARKET SHARE OF INDUSTRY LEADERS IN ASIA 158
RECEPTOR TYROSINE KINASE INHIBITORS 158
TABLE 84 ASIAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 158
FIGURE 54 ASIAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 158
NON-RECEPTOR TYROSINE KINASE INHIBITORS 158
MULTI-TARGET KINASE INHIBITORS 159
TABLE 85 ASIAN MARKET SHARE OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 159
FIGURE 55 ASIAN MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 159
SERINE/THREONINE KINASE INHIBITORS 159
TABLE 86 ASIAN MARKET SHARE OF SERINE/THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 160
FIGURE 56 ASIAN MARKET SHARES OF SERINE/THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 160
ANTIBODY KINASE INHIBITORS 160
TABLE 87 ASIAN MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS,
2010 (%) 161
FIGURE 57 ASIAN MARKET SHARES OF ANTIBODY KINASE INHIBITOR MANUFACTURERS,
2010 (%) 161
MARKET APPLICATIONS 161
MARKET REVENUE 163
TABLE 88 ASIAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS THROUGH 2016 ($
MILLIONS) 163
FIGURE 58 ASIAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS 2009-2016 ($
MILLIONS) 163
ANTINEOPLASTIC AGENTS 163
TABLE 89 ASIAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 166
FIGURE 59 ASIAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 167
IMMUNOSUPPRESSANTS 167
TABLE 90 ASIAN MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
THROUGH 2016 ($ MILLIONS) 168
FIGURE 60 ASIAN MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 168
AGE-RELATED MACULAR DEGENERATION 169
TABLE 91 ASIAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 170
FIGURE 61 ASIAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 170
Market Share 171
TABLE 92 MARKET SHARE OF KINASE INHIBITORS IN ASIA, BY APPLICATION, 2010 (%) 171
FIGURE 62 MARKET SHARE OF KINASE INHIBITORS IN ASIA, BY APPLICATION, 2010 (%) 171
CHAPTER 10 EMERGING MARKETS 173
MARKET ANALYSIS 173
TABLE 93 EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 173
FIGURE 63 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 174
TYROSINE KINASE INHIBITORS 174
TABLE 94 EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 174
FIGURE 64 EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 175
Receptor Tyrosine Kinase Inhibitors 175
EGFR 176
PDGFR 176
VEGFR 176
HER2 (Human Epidermal Growth Factor Receptor 2) 177
Market Overview 177
Market Revenue 177
TABLE 95 EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 178
FIGURE 65 EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS,
2009-2016 ($ MILLIONS) 178
Non-Receptor Tyrosine Kinase Inhibitors 179
BCR-ABL 179
Janus Kinase (JAK) Inhibitor 179
Mesenchymal Epithelial Transition Growth Factor (c-MET) 179
Spleen Tyrosine Kinase (SYK) Inhibitors 180
Market Overview 180
Market Revenue 181
TABLE 96 EMERGING MARKETS FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 181
Multikinase Inhibitors 181
Market Overview 181
Market Revenue 181
TABLE 97 EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 182
FIGURE 66 EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS,
2009-2016 ($ MILLIONS) 182
SERINE/THREONINE KINASE INHIBITORS 182
mTOR Kinase Inhibitors 182
B RAF Kinase Inhibitors 183
RHO Kinase Inhibitors 183
Cyclin-Dependant Kinase Inhibitor 183
Aurora Kinase Inhibitors 183
MAP/MEK Kinase Inhibitors 184
JNK Inhibitors 184
Protein Kinase C Inhibitors 184
PI3K Inhibitors 185
Market Overview 185
Market Revenue 186
TABLE 98 EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 186
FIGURE 67 EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016
($ MILLIONS) 186
MONOCLONAL ANTIBODIES 187
Humanized Monoclonal Antibody 188
Chimeric Monoclonal Antibody 188
Human Monoclonal Antibody 188
Market Overview 189
Market Revenue 189
TABLE 99 EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 190
FIGURE 68 EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,
2009-2016 ($ MILLIONS) 190
MARKET SHARE OF INDUSTRY LEADERS IN EMERGING MARKETS 190
RECEPTOR TYROSINE KINASE INHIBITORS 190
TABLE 100 SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010 (%) 191
FIGURE 69 SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010 (%) 191
NON-RECEPTOR TYROSINE KINASE INHIBITORS 191
MULTI-TARGET KINASE INHIBITORS 191
TABLE 101 SHARE OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN EMERGING
MARKETS, 2010 (%) 192
FIGURE 70 SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010 (%) 192
SERINE/THREONINE KINASE INHIBITORS 192
TABLE 102 SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010 (%) 192
FIGURE 71 SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010 (%) 192
ANTIBODY KINASE INHIBITORS 193
TABLE 103 SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS IN EMERGING
MARKETS 2010 (%) 193
FIGURE 72 SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS IN EMERGING
MARKETS, 2010 (%) 193
MARKET APPLICATIONS 194
MARKET REVENUE 195
TABLE 104 EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, THROUGH
2016 ($ MILLIONS) 195
FIGURE 73 EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($
MILLIONS) 195
ANTINEOPLASTIC AGENTS 196
TABLE 105 EMERGING MARKETS FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, THROUGH 2016 ($ MILLIONS) 198
FIGURE 74 EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($
MILLIONS) 198
IMMUNOSUPPRESSANTS 199
TABLE 106 EMERGING MARKETS FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS, THROUGH 2016 ($ MILLIONS) 200
FIGURE 75 EMERGING MARKETS FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS, 2009-2016 ($ MILLIONS) 200
AGE-RELATED MACULAR DEGENERATION 201
TABLE 107 EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED
MACULAR DEGENERATION, THROUGH 2016 ($ MILLIONS) 202
FIGURE 76 EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED
MACULAR DEGENERATION, 2009-2016 ($ MILLIONS) 202
MARKET SHARE 202
TABLE 108 SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION, 2010
(%) 203
FIGURE 77 SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION, 2010
(%) 203
CHAPTER 11 PATENT ANALYSIS 205
PATENTS BY YEAR 205
TABLE 109 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 205
FIGURE 78 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 205
FIGURE 79 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 (%) 206
PATENTS BY CATEGORY 206
TABLE 110 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 207
FIGURE 80 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 207
PATENTS BY TYPE 207
TABLE 111 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012 207
FIGURE 81 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012 208
TABLE 112 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 208
FIGURE 82 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 208
PATENTS BY COMPANY 209
TABLE 113 NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO
END OF FEBRUARY 2012 209
PATENTS BY COUNTRY 210
TABLE 114 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 210
FIGURE 83 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO
END OF FEBRUARY 2012 210
TABLE 115 PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010-2012 (%) 211
FIGURE 84 PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010-2012 (%) 211
PATENTS BY ASSIGNEE 212
TABLE 116 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012 212
FIGURE 85 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012 212
CHAPTER 12 CURRENT STATUS 215
CANCER AND KINASE INHIBITORS 215
MULTIPLE SINGLE KINASE INHIBITORS VERSUS SINGLE MULTIKINASE INHIBITORS 216
EFFICACY 216
RESISTANCE 216
PHARMACOKINETICS 217
Selectivity 217
TUMOR MICROENVIRONMENT 217
TOXICITY 218
FUTURE DIRECTIONS 218
CHAPTER 13 COMPANY PROFILES 220
ABBOTT LABORATORIES 220
AMGEN INC. 220
ARQULE, INC. 221
ARRAY BIOPHARMA 221
ASTRAZENECA 222
AVEO PHARMACEUTICALS, INC. 222
BAYER AG 222
BRISTOL-MYERS SQUIBB 223
BOEHRINGER INGELHEIM 223
CYTRX CORPORATION 223
EISAI INC 224
ETON BIOSCIENCE, INC. 224
EXELIXIS, INC. 225
GLAXOSMITHKLINE 225
MERCK SERONO SA 226
NOVARTIS INTERNATIONAL AG 226
OSI PHARMACEUTICALS LLC 227
PFIZER 227
ROCHE GROUP 228
S*BIO PTE LTD 228
SANOFI-AVENTIS 228
TAKEDA PHARMACEUTICALS 229
CHAPTER 14 ABBREVIATIONS 231

LIST OF TABLES
SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 6
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10
TABLE 2 HISTORY OF PROTEIN KINASES 12
TABLE 3 TYPES OF KINASE INHIBITORS 13
TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14
TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15
TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16
TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16
TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17
TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20
TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21
TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY
2012 22
TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23
TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE
INHIBITORS 24
TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE
KINASE INHIBITORS 24
TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE
KINASE INHIBITORS 24
TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE
INHIBITORS 25
TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25
TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27
TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)
TKIS 28
TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)
TKIS 28
TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
(VEGFR) TKIS 28
TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29
TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29
TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29
TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30
TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31
TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31
TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31
TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35
TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($
MILLIONS) 36
TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016 ($
MILLIONS) 40
TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH
2016 ($ MILLIONS) 43
TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($
MILLIONS) 45
TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($
MILLIONS) 49
TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 53
TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 56
TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 57
TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($
MILLIONS) 60
TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 64
TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
THROUGH 2016 ($ MILLIONS) 65
TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 67
TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 68
TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 70
TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71
TABLE 47 U.S. MARKET FOR RECEPTOR TYROS

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

  • $ 4 995
  • Industry report
  • August 2016
  • by GBI Research

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way Summary The respiratory therapy ...

Global Kinase Inhibitors Market Report 2016

Global Kinase Inhibitors Market Report 2016

  • $ 2 850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Kinase Inhibitors Report is a professional and in-depth research report on the world's major regional market conditions of the Kinase Inhibitors industry, focusing on the main regions (North ...

Global Targeted Therapy Medicine Ingredients Report-Market Size and Forecast 2016

Global Targeted Therapy Medicine Ingredients Report-Market Size and Forecast 2016

  • $ 2 850
  • Industry report
  • July 2016
  • by 9Dimen Research

2016 Global Targeted Therapy Medicine Ingredients Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Targeted Therapy Medicine Ingredients ...


ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.